ARTICLE | Clinical News

R3421: Phase II data

September 20, 2010 7:00 AM UTC

Top-line data from a double-blind, placebo-controlled Phase II trial in 87 patients showed that 20, 40 and 80 mg once-daily oral BCX4208 alone and in combination with 100, 200 or 300 mg oral allopurinol met the primary endpoint of producing a dose-dependent reduction in mean sUA concentrations from baseline to day 21. Combination treatment reduced mean sUA by 2.4-5.6 mg/dL from baseline. Additionally, BioCryst said the combination of BCX4208 and allopurinol was superior to either drug alone in reducing sUA levels. ...